These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 22433756

  • 21. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
    Tran G, Hack SP, Kerr A, Stokes L, Gibbs P, Price T, Todd C.
    Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
    [Abstract] [Full Text] [Related]

  • 22. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
    Shimada Y, Hamaguchi T, Mizusawa J, Saito N, Kanemitsu Y, Takiguchi N, Ohue M, Kato T, Takii Y, Sato T, Tomita N, Yamaguchi S, Akaike M, Mishima H, Kubo Y, Nakamura K, Fukuda H, Moriya Y.
    Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
    [Abstract] [Full Text] [Related]

  • 23. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
    Tumeh JW, Shenoy PJ, Moore SG, Kauh J, Flowers C.
    Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
    [Abstract] [Full Text] [Related]

  • 24. Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer.
    Lairson DR, Parikh RC, Cormier JN, Chan W, Du XL.
    Pharmacoeconomics; 2014 Oct; 32(10):1005-13. PubMed ID: 24920195
    [Abstract] [Full Text] [Related]

  • 25. Population-Based Cost-Minimization Analysis of CAPOX Versus Modified FOLFOX6 in the Adjuvant Treatment of Stage III Colon Cancer.
    Ho MY, Chang AY, Ruan JY, Cheung WY.
    Clin Colorectal Cancer; 2016 Jun; 15(2):158-63. PubMed ID: 26524925
    [Abstract] [Full Text] [Related]

  • 26. Current status of adjuvant therapy for colorectal cancer.
    O'Connell MJ.
    Oncology (Williston Park); 2004 May; 18(6):751-5; discussion 755-8. PubMed ID: 15214594
    [Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C, Frank M, Köhne CH, Hartmann JT, Griebsch I, Mohr A, Osowski U, Schulten J, Mittendorf T.
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [Abstract] [Full Text] [Related]

  • 28. CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.
    Loree JM, Mulder KE, Ghosh S, Spratlin JL.
    Clin Colorectal Cancer; 2014 Sep; 13(3):172-7. PubMed ID: 24630275
    [Abstract] [Full Text] [Related]

  • 29. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
    Angitapalli R, Litwin AM, Kumar PR, Nasser E, Lombardo J, Mashtare T, Wilding GE, Fakih MG.
    Oncology; 2009 Sep; 76(5):363-8. PubMed ID: 19321964
    [Abstract] [Full Text] [Related]

  • 30. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A, Peixoto RD, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Speers CH, Cheung WY.
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [Abstract] [Full Text] [Related]

  • 31. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
    Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss GR, Rivkin SE, Macdonald JS.
    J Clin Oncol; 2005 Mar 20; 23(9):1819-25. PubMed ID: 15774775
    [Abstract] [Full Text] [Related]

  • 32. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
    Chu E, Schulman KL, McKenna EF, Cartwright T.
    Clin Colorectal Cancer; 2010 Oct 20; 9(4):229-37. PubMed ID: 20920995
    [Abstract] [Full Text] [Related]

  • 33. Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial.
    Taieb J, Puig PL, Bedenne L.
    Expert Rev Anticancer Ther; 2008 Feb 20; 8(2):183-9. PubMed ID: 18279058
    [Abstract] [Full Text] [Related]

  • 34. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
    André T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Lledo G, Raoul Y, Debrix I, Buyse M, de Gramont A.
    J Clin Oncol; 2007 Aug 20; 25(24):3732-8. PubMed ID: 17704423
    [Abstract] [Full Text] [Related]

  • 35. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ.
    J Clin Oncol; 2007 Aug 10; 25(23):3456-61. PubMed ID: 17687149
    [Abstract] [Full Text] [Related]

  • 36. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A, Fléjou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C, Rougier P, de Gramont A, Bonnetain F, Praz F, Taïeb J.
    Clin Cancer Res; 2011 Dec 01; 17(23):7470-8. PubMed ID: 21998335
    [Abstract] [Full Text] [Related]

  • 37. Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.
    Miyazaki Y, Harada T, Akase T, Arakawa I, Inoue T.
    Clin Ther; 2009 Dec 01; 31 Pt 2():2433-41. PubMed ID: 20110051
    [Abstract] [Full Text] [Related]

  • 38. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
    Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG.
    J Clin Oncol; 2007 Jan 01; 25(1):102-9. PubMed ID: 17194911
    [Abstract] [Full Text] [Related]

  • 39. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
    Twelves CJ.
    Clin Colorectal Cancer; 2006 Nov 01; 6(4):278-87. PubMed ID: 17241512
    [Abstract] [Full Text] [Related]

  • 40. [Cost effectiveness analysis of two adjuvant regimens in the treatment of colorectal cancer: an interpretation of the MOSAIC Study].
    Rebesco B, Cantagalli E, Amalfitano ME.
    Tumori; 2005 Nov 01; 91(6):suppl 1-10. PubMed ID: 16457161
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.